CN1970017A - Medicament for treating ulcerative colitis and preparation process thereof - Google Patents
Medicament for treating ulcerative colitis and preparation process thereof Download PDFInfo
- Publication number
- CN1970017A CN1970017A CNA2006101676591A CN200610167659A CN1970017A CN 1970017 A CN1970017 A CN 1970017A CN A2006101676591 A CNA2006101676591 A CN A2006101676591A CN 200610167659 A CN200610167659 A CN 200610167659A CN 1970017 A CN1970017 A CN 1970017A
- Authority
- CN
- China
- Prior art keywords
- medicine
- ethanol
- ulcerative colitis
- group
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a medicament for treating ulcerative colitis and process for preparation, wherein the constituents of the raw materials include (by weight ratio) cattail pollen 7-11 parts, schisandra fruit 4-8 parts, and flavescent sophora root 2-6 parts.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of ulcerative colitis and preparation method thereof, particularly a kind of is the medicine and preparation method thereof of the treatment ulcerative colitis of feedstock production with the Chinese herbal medicine.
Background technology
Ulcerative colitis is a kind of agnogenic chronic colitis.Pathological changes mainly betides the mucosa of colon, based on ulcer, can spread all over whole colon when serious, and the acute phase mortality height, and chronic phase easily causes canceration.Clinical cardinal symptom is: diarrhoea, bloody purulent stool, stomachache and tenesmus.It is between twenty and fifty that this patient mostly is, and the course of disease is long slowly, and state of an illness weight differs, the Chang Fanfu outbreak, and sickness rate also has trend of rising in recent years.Modern medicine thinks that this disease is that self cellular immunization causes mucosa destroyed unusually, or because Nervous and Mental Factors causes the cerebral cortex moving obstacle, autonomic nervous dysfunction and to produce intestinal movement hyperfunction, intestinal vascular smooth muscle spasm is shunk, tissue ischemia, capillary permeability increases, thereby forms inflammation, erosion and the ulcer of intestinal mucosa.
At present, the method for the treatment of ulcerative colitis clinically is a lot, mainly comprises western medicine therapy, tcm therapy and acupuncture and moxibustion treatment etc.Wherein, the medicine that western medical treatment uses has norfloxacin, immunosuppressant, corticosteroid etc., ulcerative colitis state of an illness complexity, and the course of treatment is longer, and long-term a large amount of Western medicine that use are very easy to produce serious adverse effects.Acupuncture and moxibustion treatment is not very satisfactory to this sick late result.Tcm therapy adopts oral medicinal herb method or clysmata, the oral medicinal herb fado adopts powder or decoction, for example XILEI SAN, the kidney warming are held up spleen soup etc., though obtained curative effect preferably, but because diseased region is accumulated rectum and far-end colon more, the efficacy of a drug is difficult to concentrate on focus when Orally-administered decoction, powder, and herbal drug enema in treatment, though medicine can directly act on focus, medication is very inconvenient.
Summary of the invention
The medicine that the purpose of this invention is to provide a kind of treatment ulcerative colitis of determined curative effect.
For achieving the above object, the present invention takes following design: a kind of medicine for the treatment of ulcerative colitis, its composition of raw materials comprises following components by weight portion: Pollen Typhae 7-11 part, Galla Chinensis 4-8 part.
Above-mentioned prescription is the monarch drug and the ministerial drug of medicine of the present invention, in order to strengthen the curative effect of medicine of the present invention, also comprises the adjuvant drug of following portions by weight ratio in the pharmaceutical formulation of the present invention: Radix Sophorae Flavescentis 2-6 part.
The preferred parts by weight proportioning of each component of medicine is: 10 parts of Pollen Typhaes, 6.5 parts of Galla Chinensiss, 5 parts of Radix Sophorae Flavescentiss.
When needing, in said medicine, can also add one or more acceptable accessories, described adjuvant comprises diluent, excipient, filler, binding agent, wetting agent, absorption enhancer, surfactant, lubricant, stabilizing agent of pharmaceutical field routine etc., also can add flavouring agent, sweeting agent and pigment etc. in case of necessity.
This medicine can be made acceptable drug form on any galenic pharmacies such as capsule, tablet, granule, powder, oral liquid, and wherein, capsule is preferred dosage form, especially is preferably the enteric coated capsule dosage form.When adopting capsule, tablet, powder, granule, also can add in the adjuvants such as medicinal dextrin, micropowder silica gel, starch and microcrystalline Cellulose any one or a few, for example can be the dextrin and the micropowder silica gel of identical weight; The ratio of weight and number of described adjuvant and medicine material prescription total amount is 1: 20-30.
Specifically, described medicine can comprise following component: Pollen Typhae 400g, and Galla Chinensis 260g, Radix Sophorae Flavescentis 200g makes 1000 of capsules.
Second purpose of the present invention provides a kind of method for preparing above-mentioned treatment ulcerative colitis medicine.
Preparation method provided by the present invention may further comprise the steps:
1) gets material by following parts by weight proportioning: Pollen Typhae 7-11 part, Galla Chinensis 4-8 part, Radix Sophorae Flavescentis 2-6 part;
2) get Pollen Typhae and Radix Sophorae Flavescentis two flavor medical materials, add the ethanol merceration after, reflux filters, and reclaims ethanol, the concentrating under reduced pressure drying is ground into behind the fine powder standby;
3) the Galla Chinensis water is decocted, concentrate after filtering merging filtrate, add ethanol and be 60-90% to containing the alcohol amount, leave standstill after stirring evenly, filter, reclaim ethanol, be concentrated into driedly, it is standby to pulverize the back;
4) with step 2) and the medicated powder mixing of step 3) gained, the medicine of the ulcerative colitis that obtains medical treatment.
In the preparation method of above-mentioned treatment ulcerative colitis medicine, step 2) used ethanol is 60-90% ethanol in; The volume ratio of ethanol and crude drug is 4-6: 1; The merceration time is 12-36 hour, is preferably 12-18 hour; The reflux time is 1.5-5 hour.
For obtaining better drug effect, step 2) but in reflux 2-3 time, and the filtrate that obtains of will at every turn refluxing merges.
The volume ratio of water and crude drug is 4-10 when decocting crude drug in the step 3): 1, and decoct number of times and be preferably 2-4 time, decocted 1-3 hour at every turn, merge aqueous extract; Add ethanol and be preferably 85% to containing the alcohol amount; It is 0.9-1.2 that extracting solution is concentrated into relative density; The time of repose that adds behind the alcohol is 12-72 hour, is preferably 24-48 hour.
Be to improve the crude drug extraction ratio of effective constituents, described step 2) and step 3) in before lixiviate or decocting, first crude drug is ground into graininess.
In addition, the medicine of step 4) gained is encapsulated, can obtain the medicine of the treatment ulcerative colitis of capsule formulation.
The oral consumption of the adult of the medicine of above-mentioned treatment ulcerative colitis was generally 2.25-3.00g/ days, oral quite for each person every day about 7.74-13.76g crude drug, and be 10-20 days the course of treatment.
The present invention is on the basis of motherland's traditional medicine, in conjunction with the clinical research of modern medicine to ulcerative colitis treatment aspect, and with reference to the modern pharmacology achievement in research, anti-inflammation, hemostasis, astringing intestine to stop diarrhea, spasmolytic, antidiarrheal Chinese herb medicine reasonable compatibility to filtering out have obtained a kind of Chinese Traditional Medicines for the treatment of ulcerative colitis.Pollen Typhae in this medicine composition has antiinflammatory, hemostatic effect, and Galla Chinensis has antidiarrheal, astringent effect, Radix Sophorae Flavescentis have heat clearing away, antiinflammatory, effect.Compare with ulcerative colitis curative drug in the past, medicine of the present invention has the following advantages: 1) drug effect is remarkable, and this medicine causes rat acute and chronic ulcer colitis model to trinitro-benzene-sulfonic acid and has better therapeutic effect, and total effective rate reaches 100%; 2) can be made into capsule (being preferably enteric coated capsule), taking convenience, the medicine focus of going directly, onset is rapid, and therapeutic effect is good, and has no side effect; 3) preparation method is simple, and is low for equipment requirements, is convenient to apply; 4) each component is common Chinese herbal medicine, and cost is low, when having alleviated patient's slight illness, has also reduced patient's financial burden.The present invention will play a great role in the treatment of ulcerative colitis and relevant disease.
Below in conjunction with specific embodiment the present invention is described in further details.
The specific embodiment
Method therefor is conventional method if no special instructions among the following embodiment.
The medicine of embodiment 1, preparation treatment ulcerative colitis
The preparation method of the medicine of the treatment ulcerative colitis of capsule formulation of the present invention may further comprise the steps:
1) takes by weighing Pollen Typhae 400g, Galla Chinensis 260g, Radix Sophorae Flavescentis 200g;
2) be that 1: 5 70% ethanol mixes with Pollen Typhae and Radix Sophorae Flavescentis and volume ratio, merceration 12 hours, again with alcohol extract reflux 2 times, each 2 hours, the filtrates that obtain refluxing for 2 times merged the back and filter, and reclaim ethanol, were evaporated to driedly, and it is standby to pulverize the back;
3) the Galla Chinensis water is decocted 2 times, boiled 1 hour with 5 times of decoctings for the first time, boiled 1 hour with 4 times of decoctings for the second time, merge aqueous extract, being concentrated into relative density after aqueous extract is filtered is 1.05, liquid after concentrating is added ethanol to be mixed to pure content and to reach 75%, left standstill after stirring evenly 36 hours, and filtered, reclaim ethanol, be concentrated into driedly, it is standby to pulverize the back;
4) with step 2) and the medicated powder mixing of step 3) gained, the dress enteric coated capsule obtains the medicine of the treatment ulcerative colitis of capsule formulation.
The medicine of embodiment 2, preparation treatment ulcerative colitis
The preparation method of the medicine of the treatment ulcerative colitis of capsule formulation of the present invention may further comprise the steps:
1) takes by weighing Pollen Typhae 440g, Galla Chinensis 320g;
2) be that 1: 4 90% ethanol mixes with Pollen Typhae and Radix Sophorae Flavescentis and volume ratio, merceration 36 hours, again with alcohol extract reflux 3 times, 1st, 2 times 2 hours, the 3rd time 1 hour, 3 filtrates that obtain of refluxing are merged the back filtration, reclaim ethanol, be concentrated into driedly, pulverize back dress enteric coated capsule, obtain the medicine of the treatment ulcerative colitis of capsule formulation.
The medicine of embodiment 3, preparation treatment ulcerative colitis
The preparation method of the medicine of the treatment ulcerative colitis of capsule formulation of the present invention may further comprise the steps:
1) takes by weighing Pollen Typhae 420g, Galla Chinensis 240g, Radix Sophorae Flavescentis 120g;
2) be that 1: 6 60% ethanol mixes with Pollen Typhae and Radix Sophorae Flavescentis and volume ratio, merceration 24 hours, with alcohol extract reflux 1.5 hours, the filtrate that obtains refluxing filtered, and reclaims ethanol again, was concentrated into driedly, and it is standby to pulverize the back;
3) the Galla Chinensis water is decocted 4 times, boiled 3 hours with 10 times of decoctings for the first time, boiled 2 hours with 8 times of decoctings for the second time, boiled 1 hour with 6 times of decoctings for the third time, 4 times of decoctings of the 4th usefulness boiled 1 hour, merged aqueous extract, and being concentrated into relative density after aqueous extract is filtered is 1.2, the thick paste that obtains after concentrating and ethanol are mixed to pure content reach 60%, left standstill after stirring evenly 72 hours, and filtered, reclaim ethanol, be concentrated into driedly, it is standby to pulverize the back;
4) with step 2) and the medicated powder mixing of step 3) gained, the dress enteric coated capsule obtains the medicine of the treatment ulcerative colitis of capsule formulation.
The medicine of embodiment 4, preparation treatment ulcerative colitis
The preparation method of the medicine of the treatment ulcerative colitis of therapy in dry powder form of the present invention may further comprise the steps:
1) takes by weighing Pollen Typhae 440g, Galla Chinensis 320g, Radix Sophorae Flavescentis 240g;
2) be that 1: 5 75% ethanol mixes with Pollen Typhae and Radix Sophorae Flavescentis and volume ratio, merceration 18 hours, again with alcohol extract reflux 2 times, each 1.5 hours, 2 filtrates that obtain of refluxing are filtered, reclaim ethanol, be concentrated into driedly, it is standby to pulverize the back;
3) the Galla Chinensis water is decocted 3 times, boiled 3 hours with 9 times of decoctings for the first time, boiled 2 hours with 5 times of decoctings for the second time, boiled 1 hour with 4 times of decoctings for the third time, merge aqueous extract, being concentrated into relative density after aqueous extract filtered is 0.9, concentrated solution and ethanol is mixed to pure content reaches 85%, leaves standstill after stirring evenly 12 hours, filter, reclaim ethanol, be concentrated into driedly, it is standby to pulverize the back;
4) with step 2) and the medicated powder of step 3) gained mixed, add the 40g dextrin again, mixing obtains the medicine of the treatment ulcerative colitis of therapy in dry powder form.
Embodiment 5, acute toxicity testing
Detect the safety of medicine of the present invention with following experiment, concrete grammar is: with 80 Kunming mouse (body weight 22.7 ± 1.1g, female, hero half and half) be divided into 4 groups, every group 20 (female, hero half and half), the medicine of the treatment ulcerative colitis of 4 groups of mice difference gastric infusions enforcement 1, embodiment 2, embodiment 3, embodiment 4 preparations, and each different administration group is divided 4 different dosage groups (5 every group) again, dosage is followed successively by 400,600,800,1170mg/ days, continuous irrigation stomach 7 days is observed mice.Any toxic reaction does not all appear in all administration mices as a result, and 80 mices all survive, and well-grown, shows that the acute toxicity of medicine of the present invention is less, and oral safety can be for clinical use.
Embodiment 6, the present invention treat the pharmacodynamic experiment of ulcerative colitis medicine
Trinitro-benzene-sulfonic acid (TNBS) causes the model that rat acute and chronic ulcer colitis model is the ulcerative colitis of generally acknowledging in the world, trinitro-benzene-sulfonic acid (TNBS) causes ulcerative colitis by causing immune disorder, its morbidity is similar to human ulcerative colitis with the course of disease, Mucous Stool or hemafecia colon edema appear in infected animal, the intestinal wall attenuation, symptoms such as hemorrhage erosion, visible large tracts of land mucosal necrosis under the mirror, each layer of massive inflammatory cells infiltrated intestinal wall.Utilize trinitro-benzene-sulfonic acid to cause rat acute and chronic ulcer colitis model and detect the curative effect of medicine of the present invention the ulcerative colitis medicine, concrete grammar is: test is divided into normal group (normal Sprague-Dawley rat), model group (trinitro-benzene-sulfonic acid causes rat acute and chronic ulcer colitis model mouse), the positive drug matched group, administration group 1 (medicine of embodiment 1 preparation), administration group 2 (medicines of embodiment 2 preparations), administration group 3 (medicines of embodiment 3 preparations) and administration group 4 (medicines of embodiment 4 preparations) be totally 7 big groups, wherein, the used medicine of positive drug matched group is sulfasalazine sheet (available from a last HFL pharmacy lot number 050721), dosage is 0.3g/kg/ day, the medicine to be measured of 4 administration groups is followed successively by the medicine of embodiment 1-embodiment 4 preparations, each administration group is further divided into low dose group (dosage is 0.142g/kg/ day), middle dosage group (dosage is 0.285g/kg/ day) and 3 groups of high dose group (dosage is 0.571g/kg), pressed above-mentioned dosage successive administration 20 days, detect the variation of respectively organizing the interior il-1 β (IL-1 β) of rat body and controlling scorching factor interleukin-4 (IL-4) content, each organizes the variation of superoxide dismutase in the rat colon tissue (SOD) and malonaldehyde (MDA) content, and respectively organizes rat colon ulcer generation number and colon weight.
Successive administration 20 days, the proinflammatory factor il-1 β in the serum (compares * P＜0.05, * * P＜0.01, * * * P＜0.001 with normal group with the testing result of controlling scorching factor interleukin-4 content is as shown in table 1; Compare with model group, #P＜0.05, ##P＜0.01, positive controls and 4 administration groups (comprising 3 various dose groups) the intravital IL-1 β of rat content all obviously descend, and IL-4 content obviously raises; The testing result of SOD and MDA content is as shown in table 2 in the colon (compares * P＜0.05, * * * P＜0.001 with normal group; Compare with model group, #P＜0.05, ##P＜0.01, ###P＜0.001, the SOD content of positive controls and 4 administration group rat colon tissues obviously raises, and MDA content obviously descends; Each organizes the colonic ulcer generation number of rat and as shown in table 3 (with model group ratio, * P＜0.01, the ratio with model group: * * P＜0.001 of statistical result of colon weight variation; With model group ratio, #P＜0.05, compare with model group: ##P＜0.001, to compare with model group with normal group, the colonic ulcer generation digital display work of positive controls and 4 administration group rats reduces, and colon weight significantly increases.Above-mentioned experimental result shows that medicine of the present invention can obviously alleviate the symptom of colonic pathological change, and total effective rate reaches 100%, and colonic mucosal injury is had better protect and repair, can be used for treating ulcerative colitis.
Table 1 is respectively organized the variation of IL-1 β and IL-4 content in the rat blood serum
N=10)
| Group | Number of animals (only) | IL-1β(pg/mL) | IL-4(pg/mL) |
| Normal group | 10 | 80.172±15.231 | 130.037±13.079 |
| Model group | 10 | 143.051±17.585 *** | 80.160±16.395 *** |
| The positive drug matched group | 10 | 90.313±12.016 ## | 124.562±14.803 ## |
| Dosage group high dose group in the low dose group (embodiment 1 medicine group) | 10 10 10 | 141.049±8.878 ***108.702±12.362 *#113.012±8.261 **# | 96.722±16.487 ***116.483±10.667 ##120.163±11.949 # |
| Dosage group high dose group in the low dose group (embodiment 2 medicine groups) | 10 10 10 | 153.118±9.325 ***112.802±10.347 *#124.472±9.542 *# | 90.472±15.672 ***109.829±9.862 ##118.096±12.531 ## |
| Dosage group high dose group in the low dose group (embodiment 3 medicine groups) | 10 10 10 | 149.649±10.873 ***110.853±9.648 *#120.974±10.095 **# | 91.650±13.989 ***110.797±10.902 ##120.308±10.997 ## |
| Dosage group high dose group in the low dose group (embodiment 4 medicine groups) | 10 10 10 | 151.011±9.886 ***110.998±10.551 *#119.451±8.991 **# | 94.139±13.293 ***113.871±11.210 ##119.773±9.871 ## |
Annotate: compare * P＜0.05, * * P＜0.01, * * * P＜0.001 with normal group
Compare #P＜0.05, ##P＜0.01 with model group
Table 2 is respectively organized the variation of SOD and MDA content in the rat colon tissue
N=10)
| Group | Number of animals/only | SOD(U/mgprot) | MDA(nmol/mgprot) |
| Normal group | 10 | 122.252±15.227 | 14.929±2.554 |
| Model group | 10 | 60.567±10.654 *** | 37.715±4.103 *** |
| The positive drug matched group | 10 | 105.520±12.722 *### | 17.953±3.276 ## |
| Dosage group high dose group in the low dose group (embodiment 1 medicine group) | 10 10 10 | 93.118±22.012 *#114.254±17.822 ###109.251±13.697 ## | 23.175±6.705 *#17.167±3.719 ##18.599±3.070 ## |
| Dosage group high dose group in the low dose group (embodiment 2 medicine groups) | 10 10 10 | 89.338±20.337 ***110.542±18.221 *#105.982±13.731 *# | 25.173±6.072 ***19.328±3.203 ##20.612±3.401 ## |
| Dosage group high dose group in the low dose group (embodiment 3 medicine groups) | 10 10 10 | 90.774±19.031 ***111.492±19.021 *#106.448±13.443 **# | 24.992±5.998 ***18.332±3.012 ##19.552±3.571 ## |
| Dosage group high dose group in the low dose group (embodiment 4 medicine groups) | 10 10 10 | 92.761±20.881 ***113.773±19.034 *#108.217±13.023 **# | 22.493±5.992 ***18.548±3.341 ##18.673±4.021 ## |
Annotate: compare * P＜0.05, * * * P＜0.001 with normal group
Compare #P＜0.05, ##P＜0.01, ###P＜0.001 with model group
Table 3 is respectively organized colonic ulcer generation number and the colon weight of rat
N=10)
| Group | Number of animals | Ulcer generation number | Colon weight |
| Normal group | 10 | - | 2.00±0.08 |
| Model group | 10 | 5.2±1.31 | 1.24±0.07 |
| The positive drug matched group | 10 | 1.10±0.87 | 1.59±0.02 |
| Dosage high dose in the low dosage (embodiment 1 medicine group) | 10 10 10 | 2.00±1.15 *1.90±0.99 **1.10±0.99 ** | 1.30±0.02 # 1.51±0.06 ## 1.64±0.02 ## |
| Dosage group high dose group in the low dose group (embodiment 2 medicine groups) | 10 10 10 | 2.11±1.03… ***2.05±1.01 *#1.40±1.00 **# | 1.27±0.02 *** 1.47±0.52 ## 1.60±0.03 ## |
| Dosage group high dose group in the low dose group (embodiment 3 medicine groups) | 10 10 10 | 2.07±1.03 ***2.01±0.99 *#1.38±0.98 **# | 1.30±0.19 *** 1.49±0.05 ## 1.55±0.01 ## |
| Dosage group high dose group in the low dose group (embodiment 4 medicine groups) | 10 10 10 | 2.05±1.00 ***2.00±1.01 *#1.24±0.94 **# | 1.29±0.02 *** 1.50±0.03 ## 1.59±0.01 ## |
Annotate:, compare with model group: * * P＜0.001 with model group ratio, * P＜0.01
With model group ratio, #P＜0.05, compare with model group: ##P＜0.001
Claims (10)
1, a kind of medicine for the treatment of ulcerative colitis, its composition of raw materials comprises following components by weight portion: Pollen Typhae 7-11 part, Galla Chinensis 4-8 part.
2, medicine according to claim 1 is characterized in that: also comprise following components by weight portion in the composition of raw materials of described medicine: Radix Sophorae Flavescentis 2-6 part.
3, medicine according to claim 2 is characterized in that: each composition weight umber proportioning is in the described medicine: 10 parts of Pollen Typhaes, 6.5 parts of Galla Chinensiss, 5 parts of Radix Sophorae Flavescentiss.
4, medicine according to claim 1 is characterized in that: also comprise adjuvant in the described medicine, the ratio of weight and number of adjuvant and medicine material prescription total amount is 1: 20-30; Described adjuvant is any one or a few in dextrin, micropowder silica gel, starch and the microcrystalline Cellulose.
5, according to each described medicine of claim 1-4, it is characterized in that: described medicine is a capsule.
6, a kind of method for preparing the described medicine of claim 2 may further comprise the steps:
1) gets material by following parts by weight proportioning: Pollen Typhae 7-11 part, Galla Chinensis 4-8 part, Radix Sophorae Flavescentis 2-6 part;
2) get Pollen Typhae and Radix Sophorae Flavescentis two flavor medical materials, add the ethanol merceration after, reflux filters, and reclaims ethanol, the concentrating under reduced pressure drying is ground into behind the fine powder standby;
3) the Galla Chinensis water is decocted, again will aqueous extract filter the back and concentrate, in concentrate, add ethanol and be 60-90%, leave standstill after stirring evenly, filter, reclaim ethanol, be concentrated into driedly, pulverize to containing the alcohol amount;
4) with step 2) and the medicated powder mixing of step 3) gained, the medicine of the ulcerative colitis that obtains medical treatment.
7, medicine according to claim 6 is characterized in that: the ethanol described step 2) is 60-90% ethanol; The volume ratio of ethanol and crude drug is 4-6: 1; The merceration time is 12-36 hour; The reflux time is 1.5-5 hour.
8, method according to claim 6 is characterized in that: reflux is 2-3 time described step 2), and the filtrate that obtains of will at every turn refluxing merges.
9, method according to claim 6 is characterized in that: the volume ratio of water and crude drug is 4-10 when decocting crude drug in the described step 3): 1, and decocting number of times is 2-4 time, decocts 1-3 hour at every turn; Adding ethanol in concentrate is 85% to containing the alcohol amount; It is 0.9-1.2 that extracting solution is concentrated into relative density; The time of repose that adds behind the alcohol is 12-72 hour.
10, according to each described method of claim 6-9, it is characterized in that: the medicine that step 4) obtains is encapsulated, obtain the medicine of the treatment ulcerative colitis of capsule formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101676591A CN100500189C (en) | 2006-12-21 | 2006-12-21 | Medicament for treating ulcerative colitis and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101676591A CN100500189C (en) | 2006-12-21 | 2006-12-21 | Medicament for treating ulcerative colitis and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1970017A true CN1970017A (en) | 2007-05-30 |
| CN100500189C CN100500189C (en) | 2009-06-17 |
Family
ID=38111165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101676591A Expired - Fee Related CN100500189C (en) | 2006-12-21 | 2006-12-21 | Medicament for treating ulcerative colitis and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500189C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228390A (en) * | 2020-03-28 | 2020-06-05 | 西安医学院附属宝鸡医院 | Traditional Chinese medicine composition for relieving diarrhea, preparation method thereof, liquid medicament and application |
| CN115607601A (en) * | 2022-11-07 | 2023-01-17 | 新疆农业大学 | A Chinese medicinal composition for the treatment of colitis |
-
2006
- 2006-12-21 CN CNB2006101676591A patent/CN100500189C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111228390A (en) * | 2020-03-28 | 2020-06-05 | 西安医学院附属宝鸡医院 | Traditional Chinese medicine composition for relieving diarrhea, preparation method thereof, liquid medicament and application |
| CN115607601A (en) * | 2022-11-07 | 2023-01-17 | 新疆农业大学 | A Chinese medicinal composition for the treatment of colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100500189C (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN103285309B (en) | Rhodiola rosea compound composition for treating peptic ulcer | |
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN102940779A (en) | Medicine composition for treating chronic ulcerative colitis and preparation process of medicine composition | |
| CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN100500189C (en) | Medicament for treating ulcerative colitis and preparation process thereof | |
| CN101530580B (en) | Drug for curing ulcerative colitis | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN105250954B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN102631415A (en) | Traditional Chinese medicine composite as well as product and application thereof | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN1733197B (en) | Medicine for curing chronic prostatitis and process for preparing the same | |
| CN113679757B (en) | Pharmaceutical composition for improving bladder contractility and application thereof | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
| CN103127439B (en) | Traditional Chinese medicine composition for curing colonitis and enteritis | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN106266968A (en) | Herba Artemisiae Scopariae liver heat removing choleretic granules and its preparation method and application | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN100502912C (en) | Medicine for treating deficiency syndrome, its preparing process and usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20131221 |